These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38607227)

  • 1. Patients with acquired pure red cell aplasia respond to PI3Kδ inhibitor rapidly.
    Wang Z; Jiang B; Song L; Sun M; Li C; Li X; Zheng W; Tao Y; Sun Q; Qi J
    Am J Hematol; 2024 Jul; 99(7):1431-1433. PubMed ID: 38607227
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphatidylinositol 3 Kinase δ Inhibitors: Present and Future.
    Brown JR
    Cancer J; 2019; 25(6):394-400. PubMed ID: 31764120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in treatment of follicular lymphoma: efficacy of PI3Kα/δ inhibitor (TQ-B3525).
    Watanabe T
    Signal Transduct Target Ther; 2024 May; 9(1):134. PubMed ID: 38755160
    [No Abstract]   [Full Text] [Related]  

  • 4. A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy.
    Xiang Q; Dong S; Li XH
    Med Sci Monit; 2021 Oct; 27():e932772. PubMed ID: 34625526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome.
    Rao VK; Kulm E; Grossman J; Buchbinder D; Chong H; Bradt J; Webster S; Šedivá A; Dalm VA; Uzel G
    Blood Adv; 2024 Jun; 8(12):3092-3108. PubMed ID: 38593221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis.
    Yu M; Wang X; Tang Y; Wang L; Hu X; Weng Q; Wang J; Cui S
    J Med Chem; 2024 Jun; 67(11):9628-9644. PubMed ID: 38754045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia.
    Tang Y; Zheng Y; Hu X; Zhao H; Cui S
    J Med Chem; 2024 Apr; 67(8):6638-6657. PubMed ID: 38577724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.
    Paz K; Flynn R; Du J; Tannheimer S; Johnson AJ; Dong S; Stark AK; Okkenhaug K; Panoskaltsis-Mortari A; Sage PT; Sharpe AH; Luznik L; Ritz J; Soiffer RJ; Cutler CS; Koreth J; Antin JH; Miklos DB; MacDonald KP; Hill GR; Maillard I; Serody JS; Murphy WJ; Munn DH; Feser C; Zaiken M; Vanhaesebroeck B; Turka LA; Byrd JC; Blazar BR
    Am J Transplant; 2019 Jun; 19(6):1820-1830. PubMed ID: 30748099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors.
    Bahekar R; Dave B; Soman S; Patel D; Chopade R; Funde R; Kumar J; Sachchidanand S; Giri P; Chatterjee A; Mahapatra J; Vyas P; Ghoshdastidar K; Bandyopadhyay D; Desai RC
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1313-1319. PubMed ID: 30975623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitor.
    Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Suzuki D; Moritomo A; Kubo S; Nakamura K; Yamagami K; Yokoo K; Fukahori H
    Bioorg Med Chem; 2019 Mar; 27(6):1056-1064. PubMed ID: 30755348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation.
    Yang C; Xu C; Li Z; Chen Y; Wu T; Hong H; Lu M; Jia Y; Yang Y; Liu X; Deng M; Chen Z; Li Q; Ling Y; Zhou Y
    Eur J Med Chem; 2021 Nov; 223():113661. PubMed ID: 34237636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
    Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
    Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision medicine: PI3K targeting in advanced breast cancer.
    Rocca A; Melegari E; Palleschi M
    Breast Cancer Res Treat; 2019 Nov; 178(2):479. PubMed ID: 31428907
    [No Abstract]   [Full Text] [Related]  

  • 15. New and Emerging Targeted Therapies for Vascular Malformations.
    Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
    Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target.
    Henley ZA; Amour A; Barton N; Bantscheff M; Bergamini G; Bertrand SM; Convery M; Down K; Dümpelfeld B; Edwards CD; Grandi P; Gore PM; Keeling S; Livia S; Mallett D; Maxwell A; Price M; Rau C; Reinhard FBM; Rowedder J; Rowland P; Taylor JA; Thomas DA; Hessel EM; Hamblin JN
    J Med Chem; 2020 Jan; 63(2):638-655. PubMed ID: 31855425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3Kα inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma.
    Xie Q; Chi S; Fang Y; Sun Y; Meng L; Ding J; Chen Y
    Signal Transduct Target Ther; 2021 Mar; 6(1):130. PubMed ID: 33785733
    [No Abstract]   [Full Text] [Related]  

  • 18. Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors.
    Zhou H; McGowan MA; Lipford K; Christopher M; Fradera X; Witter D; Lesburg CA; Li C; Methot JL; Lampe J; Achab A; Shaffer L; Goldenblatt P; Shah S; Bass A; Schroeder G; Chen D; Zeng H; Augustin MA; Katz JD
    Bioorg Med Chem Lett; 2020 Jan; 30(1):126715. PubMed ID: 31757666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
    Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
    Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
    Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
    BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.